Edition:
United Kingdom

argenx NV (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

52.73USD
13 Dec 2017
Change (% chg)

$-2.27 (-4.13%)
Prev Close
$55.00
Open
$51.89
Day's High
$54.59
Day's Low
$51.52
Volume
191,669
Avg. Vol
18,860
52-wk High
$57.10
52-wk Low
$17.42

Select another date:

Wed, Dec 13 2017

BRIEF-Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS

* HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS

BRIEF-Argenx announces launch of proposed public offering in United States

* ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES

BRIEF-Argenx Files For Offering Of Up To $150 Mln American Depositary Shares

* ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING Source text: (http://bit.ly/2kmUxUi) Further company coverage:

BRIEF-Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110

* TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Argenx Reports Positive Topline Results From Phase 2 Trial Of ARGX-113

* REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF ARGX-113

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

* ‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​

BRIEF-Argenx 9M total comprehensive loss widens to 16.5 million euros

* REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-ArgenX launches Phase II proof-of-concept clinical trial of ARGX-113 for treatment of pemphigus vulgaris

* ARGENX LAUNCHES PHASE II PROOF-OF-CONCEPT CLINICAL TRIAL OF ARGX-113 FOR THE TREATMENT OF PEMPHIGUS VULGARIS

BRIEF-Argenx reaches 50% enrollment in phase 2 clinical trial of ARGX-113

* REG-ARGENX REACHES 50% ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF ARGX-113 IN IMMUNE THROMBOCYTOPENIA

BRIEF-ArgenX cash and cash equivalents at end H1 stood at 173.4 million euros

* H1 LOSS BEFORE TAXES EUR 7.6 MILLION VERSUS LOSS OF EUR 7.4 MILLION YEAR AGO

Select another date: